Pelthos Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $99.2M
- Price
- $25.82
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.11%
- Volume
- 17.8K
About
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Quick stats
Shares outstanding3.8M
Computed float1.4M
Float / shares36.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001919246
Websitehttps://pelthos.com
AI Summary
AI-generated1/13
majorbullishearnings
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Pelthos Therapeutics reported Q2 2026 net product revenue of $15.4 million for Zelsuvmi, representing a 45% increase from the prior quarter, driven by a 48% rise in units dispensed to 11,925.
Since its commercial launch in July 2025, Zelsuvmi has generated $42.3 million in total sales with over 25,000 patients prescribed, while the company ended the quarter with $24.2 million in cash.
Despite the revenue growth, the company posted a net loss of $(23.4) million, or $(6.62) per share, though Adjusted EBITDA improved sequentially to a loss of $(5.7) million.
Red flags
- SG&A expenses of $27.7 million significantly outpaced revenue of $15.4 million
- $0.9 million write-off of commercial API inventory due to out-of-specification quality control results
- Net loss of $(23.4) million continues to burn cash despite revenue growth